Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. US Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 

Press Releases

 
  1. Press Releases
  2. Press Statements
  3. SANOFI US PRESS KIT
  4. News Alerts
  5. Media Contacts
  6. Social Media
  7. Photos & Videos

Contact Us

Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807



 

Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education

- During Multiple Myeloma Month Sanofi Genzyme is Reinforcing its Commitment to Help Patients Live with the Second Most Common Blood Cancer in the World -

Mar 22, 2017

CAMBRIDGE, Mass., March 22, 2017 /PRNewswire/ -- Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the extension of the Multiple Myeloma Journey Partners Program that leverages storytelling as a tool to improve the patient experience with multiple myeloma. Journey Partners are multiple myeloma patients that have experienced similar emotions, faced the same challenges and asked the same questions about living with the disease. The goal is to increase reach and awareness in order to host more programs, and educate more patients and caregivers in local communities across the country.    

"Sanofi Genzyme created the Multiple Myeloma Journey Partners Program to let multiple myeloma patients know they are not alone and to provide educational resources and services that help patients and families navigate their journey to achieve the best possible outcomes," says Bhavesh Ashar, Vice President and General Manager of US Oncology, Sanofi Genzyme. "As a company, we value the importance of taking a holistic approach to patient care and transforming the patient experience. There's a real power in telling and listening to personal narratives. It helps increase the knowledge base of patients and caregivers, and makes them feel supported."   

The Multiple Myeloma Journey Partners program is a free one-hour educational seminar. The program gives people with multiple myeloma and their caregivers an opportunity to hear a Journey Partner share his or her unique patient journey with multiple myeloma and experience undergoing an autologous stem cell transplant (ASCT), considered a first-line treatment and the standard of care for treating multiple myeloma in eligible patients. During the session, patients and caregivers will also learn about helpful resources and the importance of considering a transplant evaluation.

According to John Killip, a Multiple Myeloma Journey Partner, "It was conversations with my support group, family and healthcare providers that influenced my decision to have a stem cell transplant in 2008 when I was first diagnosed with multiple myeloma at the age of 65. Mentoring other myeloma patients is one of the highlights of my life and I became a Journey Partner to share my story and help others with multiple myeloma make sense of the diagnosis and overcome the fear of the unknown." 

For information or to request a program in your area please visit www.mmjourneypartners.com. Also, patients interested in becoming a Multiple Myeloma Journey Partner can contact the program coordinator listed on the website.

About Multiple Myeloma
The second most common cancer of the blood, multiple myeloma is a cancer that starts in plasma cells, a type of white blood cell. In time, myeloma cells collect in the bone marrow. They may damage the solid part of the bone, and eventually harm other tissues and organs, such as the kidneys. Worldwide, nearly 230,000 people are living with multiple myeloma, and each year, approximately 114,000 new cases are diagnosed.

About ASCT
In an autologous transplant, a patient's own blood-forming stem cells are collected. He or she is then treated with high dose chemotherapy, or a combination of chemotherapy and radiation. The high-dose treatment kills cancer cells, but also eliminates the blood-producing cells that are left in the bone marrow. Afterward, the collected stem cells are transplanted back into the patient, allowing the bone marrow to produce new blood cells.

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Genzyme® is a registered trademark of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

 

Contacts:



Media Relations

Heather Guzzi

Tel.: (908) 981-3164

heather.guzzi@sanofi.com

Media Relations

Ashleigh Koss

Tel.: (908) 981-8745

ashleigh.koss@sanofi.com

 

 

SOURCE Sanofi

2017 News Releases


Email information entered to email a page is only used to send the message and is not retained.